 
| Course: |
Quality of Life to Predict Outcome for Older AML
|
| Target Audience: |
| This activity is intended for the oncologist. |
| Sponsor: |
| This activity is sponsored by AHC Media. |
| Accreditation: |
| AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. |
| Credit Designation: |
| AHC Media designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. |
| Faculty |
Editor
William Ershler, MD
INOVA Fairfax Hospital Cancer Center, Fairfax, VA;
Director, Institute for Advanced Studies in Aging
Washington, DC
Authors
Jerome W. Yates, MD
National Institute on Aging, NIH
Andrew S. Artz, MD
Hematology/Immunology Unit
National Institute on Aging, NIH
Peer Reviewer
V.R. Veerapalli, MD
Staff Clinician, INOVA Fairfax Cancer Center
Falls Church, VA |
| Subjects: |
- Quality of Life to Predict Outcome for Older AML
- Denosumab vs Zoledronic Acid for Patients with Prostatic Bone Metastases
- Disseminated Prostate Cancer
- Pancreatic Cancer-Associated Thrombosis: Prevention and Treatment
|
| Objectives: |
- to present the latest information regarding diagnosis and treatment of various types of cancer
- to present prevalence/surveillance data and long-term follow-up results of chemotherapy/radiation regimens
- to describe new advances in the field of oncology
|
| Financial Disclosure: |
Clinical Oncology Alert’s Editor, William Ershler, MD, authors Jerome W. Yates, MD, Andrew S. Artz, MD, and peer reviewer, V.R. Veerapalli, MD, report no financial relationships to this field of study.
Copyright 2011 AHC Media LLC. All rights reserved.
|
- You are not currently logged in.
- To view content articles and complete the post-test for this course, please login or register now
|
|
